Download video

Comprehensive Analysis of Antibody Impurities: Agilent ProteoAnalyzer & BioLC-SEC Systems

55K views

Agilent Technologies

3 months ago

Comprehensive Analysis of Antibody Impurities: Agilent ProteoAnalyzer & BioLC-SEC Systems

Comprehensive Analysis of Antibody Impurities: Agilent ProteoAnalyzer & BioLC-SEC Systems

Comprehensive Analysis of Antibody Impurities: Agilent ProteoAnalyzer \& BioLC-SEC Systems
4:00
Comprehensive Analysis of Antibody Impurities: Agilent ProteoAnalyzer \& BioLC-SEC Systems
by Agilent Technologies
【Key Message】Early Optimal Glycemic Control: a Necessity to Prevent T2D Complications
10:52
【Key Message】Early Optimal Glycemic Control: a Necessity to Prevent T2D Complications
by P2PMD
Introduction to Myositis Specific Antibodies, or MSAs
0:17
Introduction to Myositis Specific Antibodies, or MSAs
by Cure JM Foundation
Autoantibodies against Mi-2 are highly specific markers for dermatomyositis in primate liver by IIFT
0:14
Autoantibodies against Mi-2 are highly specific markers for dermatomyositis in primate liver by IIFT
by Muhannad Muhammad
Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti- PL7) antibodies by IIFT.
0:17
Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti- PL7) antibodies by IIFT.
by Muhannad Muhammad
AI Risk - Part 2 - AI Risk Typology and Taxonomy
57:28
AI Risk - Part 2 - AI Risk Typology and Taxonomy
by Audit Control Governance Risk and Compliance
Final results of a Phase II study of add-on parsaclisib for pts with MF and suboptimal rux response
1:07
Final results of a Phase II study of add-on parsaclisib for pts with MF and suboptimal rux response
by VJHemOnc – Video Journal of Hematology \& HemOnc
IndEx-2: Assessing the impact of antigen density on the efficacy \& safety of immunotherapies
29:00
IndEx-2: Assessing the impact of antigen density on the efficacy \& safety of immunotherapies
by RoukenBio
Preclinical Development of GR2002, a Novel Anti-TSLP Bispecific Antibody
2:43
Preclinical Development of GR2002, a Novel Anti-TSLP Bispecific Antibody
by Allergy
MSA Disease Karen Getting out of bed
6:45
MSA Disease Karen Getting out of bed
by Julie Perry
Female 45 YO with antisynthetase syndrome. What is the pattern of CTD-ILD on HRCT?
3:24
Female 45 YO with antisynthetase syndrome. What is the pattern of CTD-ILD on HRCT?
by Khaled Ahmed Abuzeid
How to Optimize an Antibody for Immunohistochemistry
25:01
How to Optimize an Antibody for Immunohistochemistry
by Cell Signaling Technology, Inc.
Part 2\/5: Considerations For Designing Immunohistochemical Procedures: Selecting your reagents
21:08
Part 2\/5: Considerations For Designing Immunohistochemical Procedures: Selecting your reagents
by Vector Laboratories Inc
CONTACT-03: subgroup analysis of 2L cabozantinib ± atezolizumab in aRCC
2:13
CONTACT-03: subgroup analysis of 2L cabozantinib ± atezolizumab in aRCC
by VJOncology
Understanding Myositis-Specific and Myositis-Associated Antibodies | Dr. Edminister Explains
1:04
Understanding Myositis-Specific and Myositis-Associated Antibodies | Dr. Edminister Explains
by dermatomyositis_com
The safety and efficacy of Grb2 inhibition with BP1001 in AML
1:27
The safety and efficacy of Grb2 inhibition with BP1001 in AML
by VJHemOnc – Video Journal of Hematology \& HemOnc
Refining Bispecific Antibody Engineering
51:11
Refining Bispecific Antibody Engineering
by Labroots
Primary and secondary antibodies for IHC- No case too tough
1:21
Primary and secondary antibodies for IHC- No case too tough
by Thermo Fisher Scientific
Understanding Antibody-Dependent Enhancement (ADE) - Virology Conversations
14:30
Understanding Antibody-Dependent Enhancement (ADE) - Virology Conversations
by Virology Research Services
Tackling the Complexities of Multispecific Antibodies
3:38
Tackling the Complexities of Multispecific Antibodies
by Ecolab, Purolite Resins
Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?
3:18
Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?
by VJHemOnc – Video Journal of Hematology \& HemOnc
Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resect...
3:31
Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resect...
by ecancer